Antihypertensive effects of mibefradil in the treatment of mild-to- moderate systemic hypertension

American Journal of Cardiology

Volumn 80, Issue 4 B, 1997, Pages

  Oparil, Suzanne ^a,b,c,d,e   Bernink, Peter ^a,b,c,d,e   Bursztyn, Michael ^a,b,c,d,e   Carney, Shane ^a,b,c,d,e   Kobrin, Isaac ^a,b,c,d,e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MARTINI HOSPITAL   (Netherlands)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d JOHN HUNTER HOSPITAL   (Australia)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; MIBEFRADIL; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEART RATE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SYSTOLIC BLOOD PRESSURE;

EID: 0030861535     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00565-1     Document Type: Article

References (21)

1. Kaplan N. Calcium entry blockers in the treatment of hypertension. Current status and future prospects. JAMA. 262:1989;817-823.
2. Triggle D. Calcium antagonists. Antonaccil M. Cardiovascular Pharmacology. 1990;107-160 Raven Press, New York.
3. Frishman W. Current status of calcium channel blockers. Curr Prob Cardiol. 19:1994;639-688.
4. Jones J, Gorkin L, Lian J, Staffa J, Fletcher A. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J. 311:1995;293-295.
5. 2+ channels by Ro 40-5967. Circ Res. 75:1994;144-148.
6. ++ channels. J Pharmacol Exp Ther. 271:1994;1483-1488.
7. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol. 13:1989;754-759.
8. Orito K, Satoh K, Taira N. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J Cardiovasc Pharmacol. 22:1993;293-299.
9. Clozel J-P, Osterrieder W, Kleinbloesem C, Welker A, Schläppi B, Tudor R, Hefti F, Schmitt R, Eggers H. Ro 40-5967: a new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev. 9:1991;4-17.
10. Welker H, Eggers H, Kleinbloesem C, Erb K, Breithaupt K, Butzer R, Belz G. Ro 40-5967: pharmacokinetics of a new calcium antagonist. (Abstr.). Eur J Clin Pharmacol. 36:1989;A304.
11. Portegies M, Schmitt R, Kraaij C, Braat S, Gassner A, Hagemeijer F, Pozenel H, Prager G, Viersma J, van der Wall E, Kleinbloesem C, Lie K. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol. 18:1991;746-751.
12. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther. 4:1990;731-736.
13. Schmitt R, Kleinbloesem C, Belz G, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez A, Welker H, van Brummelen P. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 52:1992;314-323.
14. Bernink P, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension. 27:1996;426-432.
15. Perski A, Ollson G, Landou C, de Faire U, Theorell T, Hamsten A. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 123:1992;609-616.
16. Oparil S, Kobrin I, Abernethy D, Levine B, Reif M, Shepherd A. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens. 10:1997;735-742.
17. Bursztyn M, Kadr H, Tilvis R, Martina B, Oigman W, Talberg J, Kobrin I. Mibefradil, a novel calcium antagonist, in elderly hypertensives: favorable hemodynamics and pharmacokinetics. Am Heart J 1997; in press.
18. Carney S, Wing L, Ribeiro A, Kallwellis R, Zimlichman R, Viskoper R, Mion D Jr, Kobrin I. The addition of mibefradil to chronic hydrocholorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens. 11:1997;387-393.
19. Furberg C, Psaty B, Meyer J. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
20. Gillum R, Makuc D, Feldman J. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 121:1991;172-177.
21. Kannel W, Kannel C, Paffenbarger R, Cupples A. Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J. 113:1987;1489-1494.